Naomi McGregor
Newcastle University(GB)
Publications by Year
Research Areas
Inflammatory Bowel Disease, PARP inhibition in cancer therapy, Gut microbiota and health, Ovarian cancer diagnosis and treatment, BRCA gene mutations in cancer
Most-Cited Works
- → Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma(2023)43 cited
- → Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer(2024)23 cited
- → Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol(2021)16 cited
- → 722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)(2021)14 cited
- → Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine(2024)12 cited
- → What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials(2024)11 cited
- → Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit(2017)6 cited
- → OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer(2017)4 cited
- → Quantifying the carbon footprint of academic clinical trials: building the evidence base and hotspot identification(2024)2 cited
- → Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota research(2024)2 cited